Medication-assisted Treatment (MAT) Market Segmentation:
Treatment Type Segment Analysis
The drug type segment in the medication-assisted treatment market is estimated to gain the largest revenue share of about 56% by 2035. The segment growth can be attributed to the factor that the pharma industry’s innovation in MAT, along with the growing awareness and acceptance of these treatments, further propels the drug-type segment expansion within the market. In addition, the market in the drug type segment is also influenced by the development of medication designed to assist individuals recovering from substance use disorder. According to recent data, substance use disorders cost employer-sponsored health insurance over USD 35 Billion in 2023.
End-User Segment Analysis
The hospital segment in the medication-assisted treatment market is estimated to gain the largest reevenue share of about 53% in the year 2035. The segment growth can be attributed to the factor that hospitals are integral in providing MAT due to their capacity for specialized care, medical expertise, and resources. In addition, hospitals often offer inpatient MAT programs, providing a controlled and supervised environment for individuals undergoing treatment. This approach allows for intensive medical monitoring and adjustment of medication dosages based on individual needs which stimulate the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
End-User |
|
